CD80 and neoplasm: A strong immunologic memory response was observed in 80% (4/5) of mice treated with ex vivo RP-B7-H3 CAR T cells, as measured by tumor rejection and/or remaining tumor-free, while 20% (1/5) developed tumors (Fig. 4n).